Grifols | GRFS - Operating Expenses

Stock Price
8.08
Daily Change
0.09 1.13%
Monthly
4.80%
Yearly
12.07%
Q2 Forecast
7.87

Grifols reported EUR1.99B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.19M 148K Sep/2025
Arca Biopharma USD 34.43M 326K Dec/2025
aTyr Pharma USD 85.61M 58.67M Dec/2025
Bio Path USD 488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD 2.24M 197K Dec/2025
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Cara Therapeutics USD 5.94M 983K Sep/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Immunic USD 25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
TherapeuticsMD USD 1.41M 50K Jun/2024